HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Appropriators Match Commissioner’s “Professional Judgment” Budget

This article was originally published in The Tan Sheet

Executive Summary

A supplemental appropriations/war funding measure containing $275 million for FDA cleared the Senate Appropriations Committee May 15 but faces a tougher go in both the House and the White House

You may also be interested in...

Bush’s Addition To 2009 Request Undermines Immediate FDA Needs – Specter

Senate Appropriations Committee member Arlen Specter says President Bush's request to add $275 million to FDA's fiscal 2009 budget request undermines efforts to increase current funding

Supplemental FDA funding

A version of the Supplemental Appropriations Bill of 2008, H.R. 2642, passed by the Senate would provide an additional $275 million for FDA, but would likely not receive President Bush's approval, the Office of Management and Budget says May 22. The president "has made clear that he will veto a bill that ... exceeds his responsible spending levels," according to OMB Director Jim Nussle. The Senate approved the measure May 15 with $100 million in additional FDA funding to regulate drugs, devices and biologics, $50 million to modernize its science and workforce, and $125 million for food protection as well as supplement support for other domestic measures, but a same-day approval by the House did not include the additional FDA funds (1"The Tan Sheet" May 19, 2008, p. 10)...

FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push

FDA's role in the handling of contaminated-heparin crisis is illustrative of "the best and the worst" of its performance under the administration, said David Nelson, senior investigator for the House Energy and Commerce Committee

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts